Login / Signup
Jing Ren
ORCID
Publication Activity (10 Years)
Years Active: 2024-2024
Publications (10 Years): 1
Top Topics
Poor Prognosis
Lps Induced
Top Venues
Current cancer drug targets
</>
This page only lists publications with an associated author ORCID identifier.
Publications
</>
Zhuanxia Dong
,
Zefeng Yang
,
Jing Ren
,
Feng Li
,
Yusheng Wang
,
Yuanyuan Yu
Envafolimab Inhibits the Growth of Gastric Cancer Cells with Low PD-L1 Expression through the DDX20/NF-κB/TNF-α Signaling Pathway.
Current cancer drug targets
(2024)